Skip to main content

Therapeutic Approach on AGE-RAGE Interaction and Its Function in Diabetic Inflammation Process

Buy Article:

$68.00 + tax (Refund Policy)

Advanced glycation end products (AGEs) are important biochemical compounds found in diabetes mellitus and are likely to be associated with an inflammatory process. Within the vessel wall, AGEs may interact with specific receptors to modulate a large number of cellular properties by activating several signaling pathways. One of these receptors is called “receptor for AGE” (RAGE). The AGE-RAGE interactions enhance transcription genes encoding for cytokines, growth factors, adhesive molecules and increased classical acute phase proteins. Potential preventive and therapeutic approaches toward diabetes and its complications include inhibition of AGE formation, breakage of preformed AGE-proteins crosslink, blockade of AGE-RAGE interactions with RAGE competitors, antibody antagonists and RAGE specific metabolic inhibition. Blockade of AGE-RAGE complex formation suppresses the levels of pro-inflammatory cytokines and growth factors and it may be considered as a target for overcoming diabetic complications. This concise review about AGE-RAGE interaction and diabetes complications discusses pathophysiological mechanisms at a glance. Patents on inhibition of AGE formation, RAGE expression and AGE-RAGE interaction are shown and discussed here.





Keywords: AGEs; Amadori's product; CML; DAG-PKC pathway; Diabetes; N-acetylcysteine; N-phenacylthiazolium-bromide; RAGE; amadorins; aminoguanidine; aminosalicyclic acid; antioxidant compounds; arylcarboxilic acid; arylpropane derivative; aspirin; benfotiamine; carboximethyl lysine; chalcone derivative; chondroitin sulfate; cytokines; diacylglycerol-protein kinase C; fluorescent cross-linking species; homopiperazine derivative; hydrazono-oxo-thiazolidine derivatives; ibuprofen; indo-methacin; inflammation; inositol; lipoic acid amide; non-fluorescent and non-cross linking species; para-aminobenzoic acid; patents; pentoxifylline; phenylguanidine; phenylpropeneamid derivative; probucol; pyridazinone derivative; pyridoxamine; synthetic AGE inhibitors; thiourea

Document Type: Research Article

Publication date: 01 November 2010

More about this publication?
  • Recent Patents on Endocrine, Metabolic & Immune Drug Discovery publishes review articles by experts on recent patents in the field of endocrine, metabolic and immune drug discovery e.g. on novel bioactive compounds, analogs & targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in endocrine, metabolic and immune drug design and discovery.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content